Skip to main content
. 2021 Feb 23;12:2040620721996488. doi: 10.1177/2040620721996488

Figure 4.

Figure 4.

Comparison between cumulative per capita healthcare costs sustained by the NHS for caring non-transplant multiple myeloma patients on first-line treatment with bortezomib or conventional chemotherapy. FABIO project, Italy, 2010–2016.

Cohort members selected with a propensity score matched design were included in this analysis. The Bang and Tsiatis estimator was used for estimating cumulative costs (see text).